Efficacy of Cabergoline in Polycystic Ovarian Syndrome and Prolactin-Related Diseases
|
Accession number;06A0891772
|
| Title;Efficacy of Cabergoline in Polycystic Ovarian Syndrome and Prolactin-Related Diseases |
| Author;
IINO YOSHIAKI
(Inouerejisukurinikku)
IO YUKO
(Inouerejisukurinikku)
TAKADA SHIN'ICHI
(Nihon Univ., School of Medicine, JPN)
AISAKA KOZO
(Odaira Memorial Tokyo Hitachi Hospital, JPN)
|
Journal Title;Ther Res
|
Journal Code:Y0681A
|
ISSN:0289-8020
|
|
VOL.27;NO.10;PAGE.2027-2032(2006)
|
| Figure&Table&Reference;FIG.3, TBL.4, REF.12 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Purpose: Since cabergoline inhibits excretion of prolactin (PRL) by predominantly acting on D2 receptors and is more long-acting than traditional drugs, it can exhibit sufficient efficacy when administered once or twice weekly. We administered the drug to patients with polycystic ovarian syndrome (PCOS), hyperprolactinemia (HPRL), occulted hyperprolactinemia (OHP) and combinations thereof, and discussed the efficacy of this drug. Method: We conducted a GnRH/TRH stimulation test in 126 outpatients complaining of menstrual irregularity or infertility; we then administered cabergoline to 13 patients with PCOS only (Group A), 65 patients with PCOS + HPRL or OHP (Group B) and 48 patients with HPRL or OHP only (Group C). Hormone kinetics, changes in symptoms and presence of pregnancy are discussed. Result: In Group C, the majority of patients experienced a normalization of their menstrual cycles, along with that of PRL; 19 of these patients achieved pregnancy with cabergoline treatment alone. In Group B, 67% of patients exhibited improvement of their LH/FSH ratio or inhibition of testosterone excretion with cabergoline treatment alone, and 8 of these patients achieved pregnancy. In Group A, there was little improvement in all patients, and combination therapy with one or more other drugs or a change in therapeutic method was necessary. In addition, among all subjects, there were no patients who discontinued administration because of adverse drug reactions, and patients welcomed the less frequent dosing of this drug. Conclusion: Cabergoline is associated with fewer adverse drug reactions, compared with bromocriptine, and requires less frequent dosing. This is considered a favorable feature. The effect was observed not only in patients with PRL-related disorders, but also in those with PCOS associated with the same disorder. Therefore, cabergoline is considered to be an effective drug as first-line treatment for the disorders mentioned above. (author abst.) |
|
|
|
Related Articles;
|
|
